Trials / Terminated
TerminatedNCT05683678
US Selumetinib Registry
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand treatment patterns and assess long-term effectiveness and safety outcomes associated with selumetinib treatment as well as to explore clinical and non-clinical factors affecting those outcomes in patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs) who started selumetinib between the ages of 2 to 18 years inclusive, and initiated selumetinib treatment on or after 10 April 2020 in a real-world setting.
Detailed description
This is a US observational registry of pediatric NF1 PN participants treated with selumetinib.
Conditions
Timeline
- Start date
- 2019-01-04
- Primary completion
- 2024-11-13
- Completion
- 2024-11-13
- First posted
- 2023-01-13
- Last updated
- 2025-04-04
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05683678. Inclusion in this directory is not an endorsement.